Behavioral Digital Biomarkers Market Size, Share & Trends Analysis Report By Type (Wearable, Mobile based Applications, Sensors), By Clinical Practice, By End-use, By Region, And Segment Forecasts, 2024 To 2030

Report Overview

Behavioral data about clinical psychiatry can be collected and analyzed, particularly with the help of electronic devices such as smartphones and wearable & implanted devices. Disease symptoms passively gathered from such devices, known as "digital health technologies," are referred to as behavioral digital biomarkers. For example, changes in speech and gait, slowed movement, and loss of automatic movements can be digitally measured to predict the presence of nervous system disorders, such as Parkinson's disease. Behavioral digital biomarkers in healthcare are still nascent but have been gaining popularity and momentum post-COVID-19 pandemic. Many market players are offering this technology, leading to a rise in their adoption. For example, Altoida is developing digital neurological disease biomarkers using machine learning and augmented reality. This technology platform allows an accurate evaluation of an individual’s functional and cognitive impairment, potential progression to Alzheimer’s disease, and symptomatic deficits due to amyloid pathology. Thus, the availability of such technologies in the market propels the market growth.

The growth of the behavioral digital biomarkers market is attributed to the rapid technological advancements in healthcare technology, the growing popularity of remote technologies and recent innovations, demand for remote patient monitoring services, and increasing healthcare expenditure. Furthermore, favorable initiatives started by the government and private organizations boost market growth. For instance, the National Alzheimer's Coordinating Center (NACC) and Gates Ventures organized the Alzheimer's Disease and Related Dementias (AD/ADRD) Digital Pilot Program to leverage digital tools to advance AD/ADRD research and discovery in 2023. The selection committee will choose one to three pilot projects. Funding of USD 0.25 to 1 million will be provided for these pilot projects that leverage technology to enable richer and more objective data collection with less burden for participants and ADRCs, advancing the development and validation of digital biomarkers for Alzheimer's. Furthermore, growing research activities and new product launch fuels the market growth. For instance, in January 2021, Biogen Inc. collaborated with Apple and conducted a new virtual research study to investigate the role of the iPhone and Apple Watch in monitoring cognitive health and screening for cognitive health decline, including mild cognitive issues. The study aims to determine digital biomarkers to aid in monitoring cognitive health and performance, including potentially identifying mild cognitive impairment, an early indicator of certain forms of dementia such as Alzheimer’s.

The behavioral digital biomarkers market has been classified into three segments, namely, type, clinical practice, and end use. The sharp rise in the usage of smartwatches, smartphones, and wearable digital technological devices such as fitness trackers and medical bracelets, as well as the continuous growth in yearly smartwatch sales, is contributing to the market's growth. Moreover, novel technology allows real-time monitoring of complicated diseases by detecting biomarkers such as speech, breathing, heat, brain health, and eye movements. For example, NEUROKEYS is a software platform that measures brain health via the energy levels of a person typing on a smartphone.

The emergence of entrepreneurial startups and the entry of niche market players offering specific solutions are boosting market growth. For example, Koneksa Health develops, tests, and validates digital biomarkers for neuroscience, Parkinson's disease, oncology, respiratory, and other therapeutic areas. Some other renowned market participants are Koneksa; Biogen Inc.; Amgen Inc.; Biogen Inc.; Empatica Inc.; Vivo Sense; and IXICO plc.

Global Behavioral Digital Biomarkers Market Report Segmentation

Grand View Research, Inc. has segmented the global behavioral digital biomarkers market report based on type, clinical practice, end-use, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Wearable

  • Mobile based Applications

  • Sensors

  • Others

• Clinical Practice Outlook (Revenue, USD Million, 2018 - 2030)

  • Diagnostic Psychiatric Digital Biomarkers

  • Monitoring Psychiatric Digital Biomarkers

  • Predictive and Prognostic Psychiatric Digital Biomarkers

  • Other's (Safety, Pharmacodynamics/ Response, Susceptibility)

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Healthcare companies

  • Healthcare Providers

  • Payers

  • Others (Patient, caregivers)

• Regional Outlook (Revenue, USD Million, 2018 - 2030

  • North America

  • U.S.

  • Canada

  • Mexico

  • Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Norway

  • Sweden

  • Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

  • Latin America

  • Brazil

  • Argentina

  • MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

• List of Key Players in Behavioral Digital Biomarkers Market

  • Koneksa

  • Biogen Inc.

  • Amgen Inc.

  • Biogen Inc.

  • Empatica Inc.

  • Vivo Sense

  • IXICO plc

  • Huma

  • Sonde Health, Inc.

  • Clario